| 1.83 Data as of May 24 |  -0.05 / -2.66%Today’s Change | 0.59 Today|||52-Week Range 2.67 | +12.27% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $71.3M |
Company Description
StemCells, Inc. engages in the research, development and commercialization of stem cell therapeutics and related tools & technologies for academia and industry. The company is focused on developing & commercializing stem and progenitor cells as the basis for novel therapeutics, therapies, cells and related tools & technologies to enable stem cell-based research and drug discovery and development. StemCells research and development efforts are focused on identifying & developing stem and progenitor cells as potential therapeutic agents. It currently have two therapeutic product development programs: the CNS program, which is developing applications for HuCNS-SC cells, the proprietary human neural stem cell product candidate, and its Liver Program, which is characterizing its proprietary human liver cells as potential therapeutic products. The company was founded by David J. Anderson and Fred H. Gage in August 1988 and is headquartered in Newark, CA.
Employees
Shareholders
| Other institutional | 5.29% |
| Individual stakeholders | 1.66% |
| Mutual fund holders | 1.58% |
Top Executives
| Martin M. McGlynn | President, Chief Executive Officer & Director |
| Ann Tsukamoto, PhD | COO, EVP-Research & Development |
| Rodney K. B. Young, MBA | Chief Financial Officer & VP-Administration |
| Stephen Huhn, MD | Vice President & Head-Neural Program |
| Paul Bello, PhD | Head-Stem Cells & Media Systems |
.
